Solutions · For providers

Know which respiratory patients need attention before the next visit.

Respiro supports respiratory remote patient monitoring (RPM) by turning everyday inhaler use into objective adherence, inhalation-technique and risk signals for clinicians, care teams and respiratory services. Patients keep using their inhalers; your team sees who is controlled, who is drifting, and what to review before the next consultation.

Before-visit adherence view Technique-risk prioritisation Clinic-ready summaries Privacy-ready deployments
What changes in your clinic

From visit snapshots to continuous respiratory context.

The provider value is not just more data. It is a clearer split of work across the people involved in care: clinicians get better visits, care teams get a prioritised panel, and respiratory services get a monitoring model that grows beyond one clinic.

Clinicians start informed

See real adherence and inhalation technique before the consultation, so the visit can focus on the patient's pattern, barriers and treatment plan rather than recollection.

Care teams prioritise outreach

Rising rescue use, missed controller doses or slipping technique can move a patient up the review queue, helping staff focus attention where it is most likely to matter.

Services scale the model

Clinic-ready summaries, panel views and integration pathways let respiratory services move from individual device data to a repeatable monitoring programme.

Breathing-risk signal

A patient who may need attention sooner.

High Elevated Low REVIEW PROMPTED Mon TODAY Tue Wed Thu Fri Sat Sun
Low Elevated High

Rising rescue-inhaler use and technique changes create an earlier care signal, prompting review on Wednesday, not only at the next scheduled appointment.

How it fits the workflow

Designed around the care team's existing rhythm.

The strongest provider programmes make the workflow explicit: enrol the right patients, capture data automatically, prioritise the panel, then review or reach out with a concise summary. Respiro is built to support that operating model without asking the clinic to run a separate device programme.

1

Enrol eligible patients

Start with the respiratory cohort where visibility would change management: uncontrolled asthma, COPD, high reliever use, recent exacerbations or therapy escalation.

2

Capture use and technique

Embedded or add-on sensing records dose timing and inhalation quality as patients use their inhalers, reducing manual logs and recall bias.

3

Prioritise the care queue

Panel views help staff sort by adherence gaps, reliever spikes, technique changes and unresolved reviews, so outreach starts with the patients most likely to need it.

4

Review, reach out, document

Clinic-ready summaries support pre-visit review, remote check-ins and documentation into the record or partner workflow where the deployment supports it.

Clinical evidence

Evidence from connected inhaler programmes.

Respiro evidence suggests that making adherence and inhalation technique visible can improve asthma control and reduce the downstream burden of poorly-controlled disease. The numbers belong to specific study populations, not a blanket promise for every clinic.

+5.9
Asthma-control points
ACT improvement vs +2.9 in control, p=0.007. Cluster RCT, n=68 · ERS 2022.
82%
Medication adherence
Mean adherence achieved in the same Respiro study population, above typical real-world levels.
73%
Technique improved
Patients improving inhaler technique in a real-world asthma and COPD service evaluation, n=59 · RDD 2026.
€466
Lower cost / patient / year
Annual saving linked to asthma control in a cluster RCT, n=68, p=0.04 · ERS 2022.

Figures come from individual Respiro studies (a cluster RCT (n=68, ERS 2022), a real-world service evaluation (n=59, RDD 2026) and earlier pilots) and describe study populations, not a promise of individual results. Conference results are labelled as such. See the evidence →

From pilot to programme

A provider deployment is a care model, not only a device rollout.

Successful connected-respiratory programmes define the clinical question first: who should be enrolled, which signals trigger review, who owns outreach, and where the summary is documented.

Respiro is designed to support that programme design across a single clinic, a respiratory service or a broader provider network, including integration and reimbursement pathways where they apply.

  • Patient selection. Define high-value cohorts: uncontrolled asthma, COPD, recent exacerbations, high rescue use or therapy escalation.
  • Alert governance. Set review thresholds, escalation rules and clinical ownership so signals become action, not noise.
  • Integration path. Use APIs, exports or partner workflows to bring summaries closer to the record and care-management tools.
  • RPM / value-based support. Device-linked data can support remote-monitoring and outcomes-based pathways, subject to market, payer and clinical requirements.
The Amiko difference

Respiro combines objective, device-linked adherence and inhalation-quality data with a regulated platform foundation: the kind of signal claims data, refill history and self-report cannot provide on their own.

Trusted by design

Patient data, protected by design.

Respiro runs on secure cloud infrastructure under an ISO 13485:2016 quality system, with GDPR- and HIPAA-aligned deployments, so the patient data you rely on is handled to medical-device standards, not bolted-on afterthoughts.

See quality & compliance

Design a provider pilot around the patients who need it most.

Let's map the cohort, workflow, review rules and evidence goals that would make Respiro useful in your clinic or respiratory service.